QT/QTc study conducted in Japanese adult healthy subjects: A novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 446-452

  Sugiyama, Atsushi ^a,b   Hashimoto, Hiroya ^c   Nakamura, Yuji ^a   Fujita, Tomoe ^d   Kumagai, Yuji ^d  

^a TOHO UNIVERSITY   (Japan)

^b Yamanashi Research Center of Clinical Pharmacology   (Japan)

^c SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^d KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

ICH E14; Japanese; moxifloxacin; QT QTc study; topiroxostat

Indexed keywords

MOXIFLOXACIN; PLACEBO; TOPIROXOSTAT;

ACUTE OTITIS MEDIA; ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSMENORRHEA; EAR PRURITUS; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERSENSITIVITY; MALE; MIDDLE AGED; NORMAL HUMAN; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ICH E14; JAPANESE; MOXIFLOXACIN; QT/QTC STUDY; TOPIROXOSTAT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; NITRILES; PYRIDINES; XANTHINE OXIDASE; YOUNG ADULT;

EID: 84898609305     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.226     Document Type: Article

References (14)

1. ICH Harmonized Tripartite Guideline. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14. Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/ Guidelines/Efficacy/E14/E14-Guideline.pdf Published May 12, 2005. Accessed January 7, 2013.
2. Darpo B,. The thorough QT study four years after the implementation of the ICH E14 guidance. Br J Pharmacol. 2010; 159: 49-57.
3. Williams EJ,. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Chem. 1949; 2: 149-168.
4. Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother. 1999; 43: 2793-2797. (Pubitemid 29519568)
5. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol. 2008; 66: 396-404.
6. Davis JD, Hackman F, Layton G, Higgins T, Sudworth D, Weissgerber G,. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol. 2008; 65 (Suppl 1): 68-75. (Pubitemid 351366541)
7. Matthys G, Park JW, McGuire S, et al. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects. Br J Clin Pharmacol. 2010; 70: 24-33.
8. Täubel J, Naseem A, Harada T, et al. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. Br J Clin Pharmacol. 2010; 69: 391-400.
9. Shin JG, Kang WK, Shon JH, et al. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol. 2007; 63: 206-215.
10. Bhole V, de Vera M, Rahman MM, Krishnan E, Choi H,. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum. 2010; 62: 1069-1076.
11. Weaver AL,. Epidemiology of gout. Cleve Clin J Med. 2008; 75 (suppl 5): S9-S12.
12. Rho YH, Zhu Y, Choi HK,. The epidemiology of uric acid and fructose. Semin Nephrol. 2011; 31: 410-419.
13. Pharmaceutical Research and Manufacturers of America QT Statistics Expert Working Team. Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations: report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team. Drug Inf J. 2005; 39: 243-266.
14. E14 Implementation Working Group ICH E14 Guideline: the Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions & Answers (R1). 2012. Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E14/E14-Q-As-R1-step4.pdf Published June 4, 2008. Updated April 5, 2012. Accessed January 7, 2013.